Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis, Filariasis
About this trial
This is an interventional treatment trial for Helminthiasis focused on measuring transmission interruption, intestinal nematodes, soil-transmitted helminths, mass drug administration, Benin, India, Malawi
Eligibility Criteria
Treatment Inclusion Criteria:
- Ages 12 months and older
Treatment Exclusion Criteria:
- Children under 12 months of age
- Pregnant women in their first trimester
- History of adverse reaction to benzimidazoles
Outcome Sampling Inclusion Criteria:
- Resident of study clusters
- Ages 12 months and older
- Willingness of adult aged 18 years and above (or age as per country specific ethical guidelines) or parent/guardian of child to provide written informed consent
- Provision of written assent to participate from children aged 8 years and above (or age as per country specific ethical guidelines)
Outcome Sampling Exclusion Criteria:
- Less than 12 months of age
- Individuals who do not typically reside in the study cluster
- Nonconsenting or assenting individuals, as applicable
Sites / Locations
- Institut de Recherche pour le DéveloppementRecruiting
- Christian Medical CollegeRecruiting
- London School of Hygiene and Tropical MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Community-wide deworming
Targeted deworming
Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.